Myriad Genetics To Present At The Goldman Sachs Global Healthcare Conference

SALT LAKE CITY, June 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35 th annual Goldman Sachs Global Healthcare Conference , at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes, California.

The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's website at www.myriad.com .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .
CONTACT: Media Contact: Ron Rogers         (801) 584-3065         rrogers@myriad.com                  Investor Contact: Scott Gleason         (801) 584-1143         sgleason@myriad.com

Myriad Genetics, Inc. Logo

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments